Anagenics Ltd has released a press release.
Lead Antibody Effective in Rare Chronic Kidney Disease
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Anagenics
- Cellmid Share Purchase Plan Completion
- Evolis USA Distribution Update
- Preliminary Final Report
- Cleansing Notice and Appendix 3B
- Cellmid Share Purchase Plan
Later from Anagenics
- Change of Registry Address: Automic P/L - Sydney Office
- Cellmids Evolis Successfully Launched in USA stores
- Ikon Legal Action - Decision
- New Patents for Midkine Antibodies in USA and Europe
- Cellmid Appoints Exclusive New Zealand Distributor
Follow Anagenics into a list and get an email when it puts out news.
Follow Anagenics